Clinical Trial Detail

NCT ID NCT03535350
Title Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Case Comprehensive Cancer Center
Indications

glioblastoma multiforme

Therapies

Ibrutinib

Ibrutinib + Temozolomide

Age Groups: senior adult

No variant requirements are available.